Sector | Chemicals | Compare with Sector peers |
Industry | Chemicals | Compare with Industry peers |
Website | http://www.sunilhealthcare.com | |
Market Cap | 63.07 Cr. | |
Enterprise Value(EV) | 104.60 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | -1.45 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
Industry PE | 44.63 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 49.66 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 1.24 | Calculated using Price: 61.50 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.03 Cr. | 10,254,750 Shares |
FaceValue | 10 | |
About Sunil Healthcare Ltd. | ||
Sunloc, a leading brand of Empty Hard Gelatin Capsules, comes from Sunil Healthcare. Having started its operations over four decades ago, is the second largest manufacturer of empty hard-shell gelatin (EHG) Capsule in India and enjoys immense credibility in various global markets. The company Introduced double-lock, triple lock and multi groove Capsules. |
1 Day |
|
+4.99% |
1 Week |
|
+6.19% |
1 Month |
|
-12.00% |
3 Month |
|
+13.49% |
6 Month |
|
+18.80% |
1 Year |
|
+5.19% |
2 Year |
|
-4.50% |
5 Year |
|
+91.01% |
10 Year |
|
+189.20% |
7 years | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 11.72 | 9.95 | -1.47 | -11.23 | -1.55 | 14.63 | 13.36 | |
Return on Capital Employed (%) | 13.8 | 11.96 | 5.56 | 0.37 | 5.26 | 14.9 | 16.11 | |
Return on Assets (%) | 4.1 | 3.39 | -0.49 | -3.7 | -0.51 | 5.58 | 5.8 |
Particulars | 8 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 43 | 47 | 47 | 45 | 44 | 50 | 56 | 54 | |
Non Curr. Liab. | 19 | 26 | 17 | 19 | 23 | 20 | 19 | 26 | |
Curr. Liab. | 60 | 68 | 74 | 66 | 54 | 40 | 45 | 51 | |
Minority Int. | |||||||||
Equity & Liab. | 123 | 142 | 138 | 130 | 121 | 110 | 121 | 131 | |
Non Curr. Assets | 62 | 73 | 72 | 71 | 72 | 75 | 73 | 70 | |
Curr. Assets | 61 | 69 | 65 | 59 | 49 | 35 | 48 | 61 | |
Misc. Exp. not W/O | |||||||||
Total Assets | 123 | 142 | 138 | 130 | 121 | 110 | 121 | 131 |
Particulars | 8 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 102 | 90 | 81 | 70 | 91 | 119 | 110 | 90 | |
Other Income | 1 | 2 | 1 | 15 | 6 | 2 | 5 | 6 | |
Total Income | 103 | 93 | 82 | 85 | 96 | 121 | 115 | 96 | |
Total Expenditure | -87 | -76 | -70 | -78 | -85 | -102 | -95 | -86 | |
PBIDT | 16 | 16 | 12 | 6 | 11 | 19 | 21 | 10 | |
Interest | -4 | -5 | -7 | -7 | -5 | -3 | -4 | -5 | |
Depreciation | -4 | -5 | -6 | -6 | -6 | -6 | -7 | -7 | |
Taxation | -3 | -2 | 0 | 2 | 0 | -3 | -3 | 1 | |
Exceptional Items | |||||||||
PAT | 5 | 4 | -1 | -5 | -1 | 6 | 7 | -1 | |
Minority Interest | |||||||||
Share Associate | |||||||||
Other Related Items | |||||||||
Consolidated Net Profit | 5 | 4 | -1 | -5 | -1 | 6 | 7 | -1 | |
Adjusted EPS | 5 | 4 | -1 | -5 | -1 | 6 | 7 | -1 |
Particulars | 7 years | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 11 | 5 | 15 | 4 | 17 | 23 | 7 | |
Cash Fr. Inv. | -13 | -17 | -3 | -3 | -11 | -4 | -3 | |
Cash Fr. Finan. | 2 | 11 | -12 | -2 | -6 | -19 | -4 | |
Net Change | 0 | -1 | 0 | 0 | -1 | 0 | 0 | |
Cash & Cash Eqvt | 1 | 1 | 1 | 1 | 1 | 0 | 1 |
Thu, 28 Mar 2024
Closure of Trading Window Trading Window of the Company shall remain close with effect from April 01 2024 till 48 hours after declaration of Audited Financial Results for the 4th quarter/ Financial year 2023-24 ended on 31st March 2024. |
Fri, 16 Feb 2024
Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper clipping regarding publication of Un-audited financial results for 3rd quarter/9 months ended on 31st December 2023 of the FY 2023-24 |
Wed, 14 Feb 2024
Approved Un-Audited Financial Results (Standalone & Consolidated) For The 3Rd Quarter/Nine Months Ended On December 31 2023 Of The Financial Year 2023-24 And Limited Review Report Thereon. Un-audited financial results (standalone and consolidated) for 3rd quarter/9months ended on 31.12.2023 of FY 2023-24 and limited review report thereon approved by the Board of Directors at their Board Meeting held today on 14th February 2024 |
Wed, 27 Mar 2024 |
Closing Below Previous Low |
Close Below Last Month Low |
High Decrease in 1 Month |
Closing Near 200 SMA |
Close Crossing 200 SMA From Above |